Global Diabetes Medicines Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Diabetes Medicines Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Diabetes Medicines are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications.

According to our (Global Info Research) latest study, the global Diabetes Medicines market size was valued at US$ 100230 million in 2023 and is forecast to a readjusted size of USD 210010 million by 2030 with a CAGR of 11.0% during review period.

Global Diabetes Medicines key players include Novo Nordisk, Sanofi, Eli Lilly, Merck & Co, Boehringer Ingelheim, etc. Global top five manufacturers hold a share over 62%.

In terms of product type, Injection is the largest segment, with a share of 60%. And in terms of application, Hospital has a share about 67 percent.

This report is a detailed and comprehensive analysis for global Diabetes Medicines market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Diabetes Medicines market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Diabetes Medicines market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Diabetes Medicines market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Diabetes Medicines market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Diabetes Medicines

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Diabetes Medicines market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, bayer, Boehringer Ingelheim, Johnson & Johnson, Takeda, Tonghua Dongbao, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Diabetes Medicines market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Oral
Injection

Market segment by Application
Hospital
Retail Pharmacy

Major players covered
Novo Nordisk
Sanofi
Eli Lilly
Merck
AstraZeneca
bayer
Boehringer Ingelheim
Johnson & Johnson
Takeda
Tonghua Dongbao
United Pharmaceuticals
Ganli Pharmaceutical
Biocon
Conker Pharmaceuticals
Jiangsu Wanbang
Geropharm
Wockhardt
Merck Serono
Novartis

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Diabetes Medicines product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Diabetes Medicines, with price, sales quantity, revenue, and global market share of Diabetes Medicines from 2019 to 2024.

Chapter 3, the Diabetes Medicines competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Diabetes Medicines breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Diabetes Medicines market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Diabetes Medicines.

Chapter 14 and 15, to describe Diabetes Medicines sales channel, distributors, customers, research findings and conclusion.